Travere Therapeutics, Inc. (TVTX) — SEC Filings
Travere Therapeutics, Inc. (TVTX) — 46 SEC filings. Latest: 8-K (May 11, 2026). Includes 17 8-K, 12 SC 13G/A, 6 10-Q.
View Travere Therapeutics, Inc. on SEC EDGAR
Overview
Travere Therapeutics, Inc. (TVTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 16, 2026: On April 15, 2026, Travere Therapeutics, Inc. filed a Form 4, indicating changes in beneficial ownership of securities. The report covers the period ending April 13, 2026. Elizabeth E. Reed is listed as the reporting person.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 2 bullish, 44 neutral. The dominant filing sentiment for Travere Therapeutics, Inc. is neutral.
Filing Type Overview
Travere Therapeutics, Inc. (TVTX) has filed 2 4, 1 144, 17 8-K, 1 FWP, 6 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of TVTX's 27 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $164,859,000 |
| Net Income | $25,700,000 |
| EPS | $0.29 |
| Debt-to-Equity | 6.32 |
| Cash Position | $110,930,000 |
| Operating Margin | 15.1% |
| Total Assets | $538,581,000 |
| Total Debt | $311,370,000 |
Key Executives
- Elizabeth E. Reed
- Dr. John F. McDonald
- Dr. David E. Rickman
- Ms. Jennifer L. D. Fox
- Ms. Sarah K. Kelly
- Dr. Blake C. Roberts
- Dr. Philip J. Louis
- Dr. Jonathan M. Kay
- Mr. David E. R. Johnson
- Mr. Ian F. Smith
Industry Context
The rare disease pharmaceutical sector is characterized by high R&D costs, significant regulatory hurdles, and the potential for substantial returns upon successful drug commercialization. Companies like Travere Therapeutics focus on unmet medical needs, often facing competition from both established players and emerging biotechs. The industry is driven by scientific innovation, patent protection, and effective market access strategies.
Top Tags
institutional-ownership (5) · 10-Q (4) · sec-filing (4) · amendment (4) · Biotechnology (3) · address-change (3) · financials (3) · pharmaceuticals (3) · 8-k (3) · 8-K (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $25.7M | Significant turnaround from a $54.8 million net loss in Q3 2024. |
| Total revenue for Q3 2025 | $164.9M | Increased from $62.9 million in Q3 2024, demonstrating strong growth. |
| Net product sales for Q3 2025 | $113.2M | Major component of revenue growth, up from $61.0 million in Q3 2024. |
| License and collaboration revenue for Q3 2025 | $51.7M | Substantial increase from $1.9 million in Q3 2024, driven by milestone payments. |
| Net loss for nine months ended Sept 30, 2025 | $28.3M | Reduced significantly from a $261.3 million net loss in the prior year period. |
| Total revenue for nine months ended Sept 30, 2025 | $361.0M | More than doubled from $158.4 million in the prior year period. |
| Cash and cash equivalents as of Sept 30, 2025 | $110.9M | Increased from $58.5 million at December 31, 2024, improving liquidity. |
| Regulatory milestone payment | $17.5M | Received in May 2025 for FILSPARI's standard MA approval in Europe. |
| Market access milestone payment | $40.0M | Recognized in September 2025 for FILSPARI in certain countries. |
| Shares outstanding as of Oct 27, 2025 | 89,472,327 | Reflects the current share count for valuation. |
| Q2 2025 Product Revenue | $366M | Increased from $347M in Q2 2024, showing 5.5% growth. |
| H1 2025 Total Revenue | $430M | Increased from $337M in H1 2024, representing 27.6% growth. |
| H1 Revenue Growth | 27.6% | Significant year-over-year increase for the first half of 2025. |
| Period End Date | 2025-03-31 | Latest reported quarter |
| Period Start Date | 2025-01-01 | Latest reported quarter |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Travere Therapeutics, Inc. (TVTX)?
Travere Therapeutics, Inc. has 46 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 12 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TVTX filings?
Across 46 filings, the sentiment breakdown is: 2 bullish, 44 neutral. The dominant sentiment is neutral.
Where can I find Travere Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Travere Therapeutics, Inc. (TVTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Travere Therapeutics, Inc.?
Key financial highlights from Travere Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TVTX?
The investment thesis for TVTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Travere Therapeutics, Inc.?
Key executives identified across Travere Therapeutics, Inc.'s filings include Elizabeth E. Reed, Dr. John F. McDonald, Dr. David E. Rickman, Ms. Jennifer L. D. Fox, Ms. Sarah K. Kelly and 5 others.
What are the main risk factors for Travere Therapeutics, Inc. stock?
Of TVTX's 27 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Travere Therapeutics, Inc.?
Forward guidance and predictions for Travere Therapeutics, Inc. are extracted from SEC filings as they are enriched.